Qtrex Quantum Ltd (QTEX) Stock Analysis
Verdict: AVOID
Pre-revenue acute care medtech with severe cash burn (~3.8 months runway) faces imminent dilution risk despite short-term speculative momentum.
Investment score: 32/100
Analysis as of
Is Qtrex Quantum Ltd stock worth reviewing? AI model thesis
The AI model assigns an AVOID rating due to a critical liquidity shortfall (cash runway under 4 months) and annual FCF burn of -$9.96M, making severe equity dilution highly probable despite recent price spikes.
7-factor investment score
- Valuation: 10/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 50/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Qtrex Quantum Ltd opportunities and risks
What speaks for QTEX
- INSPIRA ART100 Commercial Ramp
What speaks against QTEX
- Imminent Capital Raise and Share Dilution
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| INMD | 11.3x | 2.2x | 5.0x | 76.5% | 20.7% | 10.8% |
| Peer median | 11.3x | 2.2x | 5.0x | 76.5% | 20.7% | 10.8% |
Frequently asked questions about Qtrex Quantum Ltd (QTEX)
Is QTEX stock a good investment?
The cached TradeMates AI model rates Qtrex Quantum Ltd as AVOID with an investment score of 32/100. The AI model assigns an AVOID rating due to a critical liquidity shortfall (cash runway under 4 months) and annual FCF burn of -$9.96M, making severe equity dilution highly probable despite recent price spikes. This is algorithmic model output, not personal investment advice.
Is QTEX stock a buy?
The TradeMates model verdict for QTEX is AVOID with an investment score of 32/100. Treat this as a model signal to review, not a personal buy recommendation.